<DOC>
	<DOCNO>NCT00661375</DOCNO>
	<brief_summary>To evaluate efficacy , safety , pharmacokinetics BAY 43-9006 patient unresectable and/or metastatic renal cell cancer ( RCC ) fail least one cytokine contain regimen .</brief_summary>
	<brief_title>BAY43-9006 Phase II Study Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients suffer unresectable and/or metastatic , measurable RCC histologically cytologically document . Patients rare subtypes RCC , pure papillary cell tumor , mixed tumor contain predominantly sarcomatoid cell , Bellini carcinoma , medullary carcinoma , chromophobe oncocytic tumor , exclude study participation . More three regimen previous treatment RCC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>BAY 43-9006</keyword>
	<keyword>Phase II</keyword>
	<keyword>Renal cell carcinoma</keyword>
	<keyword>Response rate</keyword>
</DOC>